KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Kiniksa Pharmaceuticals International, plc Share Price
Equities
KNSA
GB00BRXB0C07
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.1 USD | +3.52% |
|
+3.08% | +8.89% |
| 01/07 | Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf | MT |
| 26/06 | Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday | MT |
| Sales 2024 * | 389M 32.48B | Sales 2025 * | 536M 44.75B | Capitalization | 1.31B 109B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -584M | Net income 2025 * | 42M 3.5B | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | 242M 20.21B | Net cash position 2025 * | 386M 32.21B | EV / Sales 2025 * | 1.73 x |
| P/E ratio 2024 * |
-173
x | P/E ratio 2025 * |
31.6
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals International, plc
More recommendations
More press releases
| 1 day | +2.17% | ||
| 1 week | +1.89% | ||
| Current month | +1.13% | ||
| 1 month | -4.21% | ||
| 3 months | +3.51% | ||
| 6 months | -5.51% | ||
| Current year | +7.64% |
1 week
17.38
19.02
1 month
17.3819.81
Current year
16.5622.09
1 year
13.5622.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 01/15/01 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 01/15/01 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 01/15/01 |
Barry Quart
BRD | Director/Board Member | 67 | 01/15/01 |
Thomas Malley
BRD | Director/Board Member | 55 | 01/16/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 19.1 | +3.52% | 221 240 |
| 02/24/02 | 18.45 | +2.50% | 413,389 |
| 01/24/01 | 18 | -3.59% | 530,300 |
| 28/24/28 | 18.67 | +0.43% | 1,825,928 |
| 27/24/27 | 18.59 | +0.32% | 409,484 |
Delayed Quote Nasdaq, July 03, 2024 at 09:34 pm IST
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
18.45
USD
Average target price
30.67
USD
Spread / Average Target
+66.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.64% | 1.31B | |
| +15.08% | 122B | |
| +16.20% | 113B | |
| +17.55% | 26.22B | |
| -24.23% | 19.01B | |
| -19.14% | 15.71B | |
| -17.93% | 15.22B | |
| -46.81% | 14.72B | |
| +57.17% | 14.58B | |
| +4.75% | 13.84B |
- Stock Market
- Equities
- KNSA Stock
